Targeting spike protein-induced TLR/NET axis by COVID-19 therapeutic NRICM102 ameliorates pulmonary embolism and fibrosis.
Pharmacol Res
; 184: 106424, 2022 10.
Article
en En
| MEDLINE
| ID: mdl-36064077
Palabras clave
3-caffeoylquinic acid (PubChem CID: 1794427); 4-caffeoylquinic acid (PubChem CID: 9798666); 5-caffeoylquinic acid (PubChem CID: 5280633); Baicalin (PubChem CID: 64982); COVID-19; Glycyrrhizic acid (PubChem CID: 14982); NRICM102; Norwogonin 7-glucuronide (PubChem CID: 44258552); Oroxyloside (PubChem CID: 14655552); Pulmonary embolism; Pulmonary fibrosis; Quercetin 3-galactoside (PubChem CID: 5281643); Quercetin 3-glucoside (PubChem CID: 5280804); Quercetin 3-rhamnoside (PubChem CID: 5280459); Traditional Chinese medicine
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Embolia Pulmonar
/
Lesión Pulmonar
/
Tratamiento Farmacológico de COVID-19
Límite:
Humans
Idioma:
En
Revista:
Pharmacol Res
Asunto de la revista:
FARMACOLOGIA
Año:
2022
Tipo del documento:
Article
País de afiliación:
Taiwán